glp-1 approval Continued growth for receptor agonists and SGLT-2 inhibitors in 2017 FDA Approves First Generic GLP-1

Always consult your physician or a qualified healthcare provider for personalized medical advice and before making any decisions about your health or treatment.

GLP-1 Receptor Antagonists: This drug class blocks GLP-1 receptor signalling to reduce exaggerated insulin secretion after meals, helping control postprandial hypoglycemia in PBH

A 2025 study including Fitzpatrick type IIIIV skin (typical of South Asian complexions) showed good results and tolerability

Metabolic Effects: Treatment was associated with improvements in fasting glucose levels and insulin sensitivity

Headache, upper respiratory symptoms, or mild stomach upset may also occur